We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
- Authors
Abbink, E J; Pickkers, P; Jansen van Rosendaal, A; Lutterman, J A; Tack, C J; Russel, F G M; Smits, P
- Abstract
Glibenclamide attenuates the protective responses to opening of vascular ATP-sensitive potassium (K(ATP)) channels during ischaemia. Therefore, glibenclamide treatment of Type 2 diabetes mellitus may have hazardous cardiovascular effects when used under conditions of ischaemia. Glimepiride and metformin seem to lack such characteristics. Based on these data, we hypothesized that, in contrast to glibenclamide, chronic treatment of Type 2 diabetic patients with glimepiride or metformin will not impair the vasodilator function of K(ATP) opening in vivo.
- Publication
Diabetic medicine : a journal of the British Diabetic Association, 2002, Vol 19, Issue 2, p136
- ISSN
0742-3071
- Publication type
Journal Article
- DOI
10.1046/j.1464-5491.2002.00663.x